Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pa...
Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.64) by 1...
First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reportedPromising anti-tu...
GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more...
Cantor Fitzgerald analyst Eric Schmidt assumes Verastem (NASDAQ:VSTM) with a Overweight rating.
BTIG analyst Justin Zelin reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $20 price target.
GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 do...
